Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1419 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10019.124 | 0.9937 | 0.9766 | 0.5356 | |
| HCC1419 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10019.124 | 1.0150 | 1.0564 | 0.5356 | |
| HCC1419 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10019.124 | 1.0082 | 1.0306 | 0.5356 | |
| HCC1419 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10019.124 | 0.8987 | 0.6382 | 0.5356 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 7441.102 | 0.9783 | 0.9526 | 0.9144 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 7441.102 | 1.0603 | 1.1321 | 0.9144 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 7441.102 | 0.9955 | 0.9902 | 0.9144 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 7441.102 | 1.0183 | 1.0400 | 0.9144 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 7441.102 | 1.0299 | 1.0655 | 0.9144 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 7441.102 | 0.9897 | 0.9774 | 0.9144 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 7441.102 | 0.9953 | 0.9897 | 0.9144 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 7441.102 | 1.0138 | 1.0302 | 0.9144 | |
| HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 7441.102 | 0.9685 | 0.9313 | 0.9144 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 7447.102 | 0.9774 | 0.9725 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 7447.102 | 0.9942 | 0.9929 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 7447.102 | 0.9757 | 0.9704 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 7447.102 | 0.9144 | 0.8942 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 7447.102 | 0.8565 | 0.8205 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 7447.102 | 0.8572 | 0.8213 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.288 | uM | 7447.102 | 0.8792 | 0.8496 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 1.44 | uM | 7447.102 | 0.8830 | 0.8544 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 7.2 | uM | 7447.102 | 0.7858 | 0.7277 | 1.6467 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9347.026 | 1.0854 | 1.1304 | 1.2965 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9347.026 | 0.9872 | 0.9802 | 1.2965 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9347.026 | 1.1106 | 1.1685 | 1.2965 |